The tech behind the first FDA-approved CAR-T cell therapy – OutSourcing-Pharma.com
OutSourcing-Pharma.com |
The tech behind the first FDA-approved CAR–T cell therapy
OutSourcing-Pharma.com The manufacturing process for Novartis' chimeric antigen receptor T cell (CAR–T) cell therapy, Kymriah, requires the reprogramming of a patient's T cells. T cells, or T lymphocytes, are a subtype of white blood cell and play a key role in cell-mediated … |
